This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA experts were retained on behalf of a multinational biopharmaceutical manufacturer to evaluate expected damages from terminating a co-promotion agreement with another manufacturer in a major ex-US market.
CRA’s team evaluated the present value of the co-promotion partner’s lost profits under the co-promotion agreement using a range of forecasts and other assumptions. CRA’s approach and results were ultimately presented to senior management.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comDear Clients and Friends, Our activities in 2024 reflected ongoing trends from 2023 and emerging forces affecting the landscape for investors and companies...
2023 marked a significant surge in activity across diverse sectors such as mining, oil & gas, the energy transition, pharma, and merger disputes. Throughout...
